News

Gustave Roussy Authorised to Conduct Phase I Clinical Trials in Nuclear Medicine

In 2024, the Nuclear Safety and Radiation Protection Authority (ASNR) and the Regional Health Agency (ARS) Île-de-France authorised Gustave Roussy to conduct Phase I trials in nuclear medicine, the first stage in the clinical validation process of a new treatment.

Published on

Service de  médecine nucléaire

In 2024, the Nuclear Safety and Radiation Protection Authority (ASNR) and the Regional Health Agency (ARS) Île-de-France authorised Gustave Roussy to conduct Phase I trials in nuclear medicine, the first stage in the clinical validation process of a new treatment. The Institute can now evaluate innovative radioligands administered for the first time or at an early stage in humans. Previously, the Nuclear Medicine Division at Gustave Roussy, part of the Medical Imaging Department, was authorised to treat patients with these drugs once they were commercially available or in Phase II-III development.

Service de  médecine nucléaire

Radionuclide therapy (RNT) is a nuclear medicine treatment modality currently undergoing numerous innovations. It involves administering a radioactive drug (radiopharmaceutical) specifically designed to target tumour cells, thereby destroying them while preserving healthy tissue.

Several innovative radiopharmaceuticals are under development. Gustave Roussy is now authorised to conduct Phase I trials in nuclear medicine to assess these new treatments in humans for the first time or at an early stage. The Institute also aims to contribute to developing innovative multimodal therapeutic strategies.

► Watch the video on Youtube

First Patient Treated

In January 2025, the nuclear medicine division at Gustave Roussy, in collaboration with the Department of Therapeutic Innovation and Early Trials (DITEP), treated its first patient in a Phase I nuclear medicine clinical trial. The patient, diagnosed with metastatic breast cancer, received [177Lu]Lu-NeoB, a radiopharmaceutical targeting the bombesin receptor, which is frequently overexpressed in certain cancers, including breast cancer.

This first administration marks the official launch of Phase I clinical trials in this field, an area that remains underdeveloped in France and Europe due to significant organisational and regulatory constraints.

"Obtaining ASNR authorisation in 2024 was made possible thanks to the infrastructure and expertise developed at Gustave Roussy. We had to demonstrate our ability to ensure a safe pathway for both patients and healthcare professionals, to maintain laboratories capable of handling radioligands, and to conduct precise dosimetry analyses for each administration. The team successfully met these challenges by establishing the entire framework necessary to carry out these studies," said Dr Désirée Deandreis, Head of the Nuclear Medicine Division at Gustave Roussy.

Commitment to Innovation

In the coming months and years, Gustave Roussy plans to expand its trials and broaden radiopharmaceutical indications to other tumour types, including digestive, pancreatic, lung, and brain cancers. The long-term goal is to further enhance the Institute’s capacity to conduct these studies by equipping its radiopharmacy for the in-house production of innovative radiopharmaceuticals.

Through this ambitious programme, Gustave Roussy reaffirms its commitment to innovation and clinical research, striving to provide patients with increasingly targeted and effective treatments.

Last news

  • Two photon-counting CT scanners now equip Gustave Roussy's imaging department

    Since September 2026, Gustave Roussy's Department of Medical Imaging has been equipped with a second photon-counting CT scanner, delivering higher image resolution while reducing the doses of X-rays and contrast agent administered to patients. This technology recently enabled the Institute to perform an iodine-free pulmonary CT angiogram, a world first.

    Photographie du scanner à comptage photonique
  • Prevention and screening: getting ahead of lung cancer

    To mark Thoracic Cancer Awareness Month and Tobacco-Free Month, two campaigns focusing on lung cancer, Gustave Roussy highlights its initiatives to advance prevention and screening among people at increased risk. Since its creation in 2021, the Institute’s Interception Lung programme has welcomed more than 900 participants, supporting them to stop smoking and offering personalised screening for the disease.

    Photographie : patient effectuant un scanner thoracique et équipes soignantes
  • Gustave Roussy Meets His Audience

    As part of its awareness-raising and fundraising efforts, Gustave Roussy is currently conducting a door-to-door outreach campaign in several towns in Val-de-Marne (Fresnes, Vitry-sur-Seine, Nogent-sur-Marne, Bry-sur-Marne, Le Kremlin-Bicêtre) from Monday through Saturday, 1:30 p.m. to 8:00 p.m.

    Deux personnes en charge de la collecte porte-à-porte
  • Mens November: Take care of your jewelry its precious!

    November is the month dedicated to raising awareness and promoting prevention of male cancers, which include prostate, testicular, and penile cancers. The goal is to raise public awareness of these diseases—which account for approximately 63,000 new cases in France each year—and to encourage men to perform testicular self-exams, a simple step that can help detect a lump, the nature of which must then be determined through further medical examinations. Gustave Roussy has extensive expertise in the treatment of male cancers, particularly through its Genitourinary Oncology Committee, which is deeply involved in research on these diseases. 

    Visuel fixe campagne novembre masculin